CJC-1295 and ipamorelin are both GH secretagogues documented to stimulate GH release in animal models and human studies. However, the specific claim that CJC/ipamorelin will 'tank' natural GH production in a 23-year-old requires evidence of suppression—the literature shows these compounds stimulate GH acutely, but long-term suppression of endogenous production in young males is not established in published human trials. Raun et al. (1998, PMID 9849822) confirmed ipamorelin's selectivity for GH secretion with minimal prolactin/cortisol effect, but did not measure endogenous GH axis suppression.

CJC-1295 and ipamorelin are recognized GH secretagogues that function specifically by targeting the pituitary gland and growth hormone-releasing hormone (GHRH) pathways. Raun et al. (1998) and subsequent ipamorelin literature confirm mechanism of action at the pituitary level. This claim's direction is well-established, though the creator has not specified whether the effect is temporary (acute stimulation) or pathological (chronic dysfunction).

Both CJC-1295 and ipamorelin are documented to increase GH levels acutely when administered; however, the claim 'lower hormone levels' is ambiguous and may conflate acute suppression with chronic use effects. The peptide profile notes ipamorelin has 'minimal effect on cortisol or prolactin,' suggesting selectivity. Without specification of which hormones, which timeframe, or which direction (lower vs. higher), this claim lacks precision, but the mechanistic basis for hormonal modulation is supported by GH secretagogue literature.

No published human or animal studies examining CJC-1295 or ipamorelin effects on fertility parameters (sperm count, testosterone, LH/FSH, reproductive outcomes) were identified in PubMed or clinical trial registries. GH itself has complex reproductive effects (literature exists on growth hormone and gonadal function), but direct evidence for this specific peptide combination and fertility is absent.